Algeta
Algeta ASA (ALGETA:NO) was founded in 1997 by Roy H. Larsen and Øyvind S. Bruland in Oslo, Norway as a private biotechnology and pharmaceutical company. The company’s research and development focus lies in the field of alpha-particle emitting radiopharmaceuticals. The lead product of the company, Xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer treatment.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Algeta
Algeta ASA (ALGETA:NO) was founded in 1997 by Roy H. Larsen and Øyvind S. Bruland in Oslo, Norway as a private biotechnology and pharmaceutical company. The company’s research and development focus lies in the field of alpha-particle emitting radiopharmaceuticals. The lead product of the company, Xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer treatment.
has abstract
Algeta ASA (ALGETA:NO) was fou ...... aceutics for cancer treatment.
@en
founding year
industry
product
type
Link from a Wikipage to an external page
Wikipage page ID
43,190,981
page length (characters) of wiki page
Wikipage revision ID
1,018,241,928
Link from a Wikipage to another Wikipage
foundation
homepage
industry
name
Algeta ASA
@en
products
type
Acquired by Bayer AG in December 2013
@en
wikiPageUsesTemplate
subject
sameAs
comment
Algeta ASA (ALGETA:NO) was fou ...... aceutics for cancer treatment.
@en
label
Algeta
@en
wasDerivedFrom
homepage
isPrimaryTopicOf
name
@en
Algeta ASA
@en